[
  {
    "ts": null,
    "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?",
    "url": "https://finnhub.io/api/news?id=90461fe2b10ef9c117a39ff656e5a36792ceef896cca2c913a981ad8f3b24764",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768855440,
      "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
      "id": 138180931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?",
      "url": "https://finnhub.io/api/news?id=90461fe2b10ef9c117a39ff656e5a36792ceef896cca2c913a981ad8f3b24764"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance",
    "summary": "Invesco Equity And Income Fund's Q4 2025 report highlights strategic shifts toward AI-driven electronics and medical diagnostics. Read the full analysis now.",
    "url": "https://finnhub.io/api/news?id=8fa0e8a042c25f853ecd5bad09f8c876e3d807104ce7543c9a5c9a3a621af195",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768853400,
      "headline": "Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance",
      "id": 138181758,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2236985195/image_2236985195.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Invesco Equity And Income Fund's Q4 2025 report highlights strategic shifts toward AI-driven electronics and medical diagnostics. Read the full analysis now.",
      "url": "https://finnhub.io/api/news?id=8fa0e8a042c25f853ecd5bad09f8c876e3d807104ce7543c9a5c9a3a621af195"
    }
  },
  {
    "ts": null,
    "headline": "Congresswoman Violates STOCK Act With Over 200 Late Trade Disclosures: Purchases Include Mag7, Healthcare Stocks",
    "summary": "Rep. Julia Letlow (R-La.) reportedly violated a federal transparency law by failing to disclose her personal stock trades within the required time frame. Lawmaker Missed STOCK Act Trade Filings Letlow, a third-term Louisiana congresswoman, failed to disclose 224 stock and bond trades within the 45-day reporting window required under the Stop Trading on Congressional Knowledge (STOCK) Act, reported NOTUS on Thursday. Letlow also amended all five of her annual financial disclosures dating back to",
    "url": "https://finnhub.io/api/news?id=52a86d894e854b8bc3ddce2e1a7b7ed746942a5921d3267cb29d669d7e0f95fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768833076,
      "headline": "Congresswoman Violates STOCK Act With Over 200 Late Trade Disclosures: Purchases Include Mag7, Healthcare Stocks",
      "id": 138177907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Rep. Julia Letlow (R-La.) reportedly violated a federal transparency law by failing to disclose her personal stock trades within the required time frame. Lawmaker Missed STOCK Act Trade Filings Letlow, a third-term Louisiana congresswoman, failed to disclose 224 stock and bond trades within the 45-day reporting window required under the Stop Trading on Congressional Knowledge (STOCK) Act, reported NOTUS on Thursday. Letlow also amended all five of her annual financial disclosures dating back to",
      "url": "https://finnhub.io/api/news?id=52a86d894e854b8bc3ddce2e1a7b7ed746942a5921d3267cb29d669d7e0f95fb"
    }
  },
  {
    "ts": null,
    "headline": "MoneyShow's Best Investment Ideas For 2026: Part 7",
    "summary": "MoneyShow presents top investment ideas for 2026 from leading advisors. Part 7 includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.",
    "url": "https://finnhub.io/api/news?id=482eab100e99dd982f175182032352444338ce002872fb679fd45a1f0e4f3bb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768832400,
      "headline": "MoneyShow's Best Investment Ideas For 2026: Part 7",
      "id": 138179951,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153471752/image_2153471752.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "MoneyShow presents top investment ideas for 2026 from leading advisors. Part 7 includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.",
      "url": "https://finnhub.io/api/news?id=482eab100e99dd982f175182032352444338ce002872fb679fd45a1f0e4f3bb1"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Pfizer's Non-Oncology Business in Q4?",
    "summary": "PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.",
    "url": "https://finnhub.io/api/news?id=9d9a55221c7cabf25da1878a53208465bc3c6639f9dce083cc975a8e8e3eb4a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768831260,
      "headline": "What to Expect From Pfizer's Non-Oncology Business in Q4?",
      "id": 138178028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.",
      "url": "https://finnhub.io/api/news?id=9d9a55221c7cabf25da1878a53208465bc3c6639f9dce083cc975a8e8e3eb4a8"
    }
  },
  {
    "ts": null,
    "headline": "AI in Drug Discovery Market Research Report 2026-2040: NVIDIA, Insilico Medicine, Google DeepMind, Pfizer, and Roche Leveraging AI Platforms to Accelerate Development Timelines and Reduce R&D Costs",
    "summary": "AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom therapies. The market will grow due to investments, collaboration, and AI's role in addressing rising chronic conditions.Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The \"AI in Drug Discovery Market, till 2040: Distribution by Drug Discovery Steps, Therapeutic Area, and Key Geographical Regions: Industry Tr",
    "url": "https://finnhub.io/api/news?id=b550283fed8c2379bd057fdd19efb3af9179be0faf1ae9f00d9360c8b9293071",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768813320,
      "headline": "AI in Drug Discovery Market Research Report 2026-2040: NVIDIA, Insilico Medicine, Google DeepMind, Pfizer, and Roche Leveraging AI Platforms to Accelerate Development Timelines and Reduce R&D Costs",
      "id": 138175720,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom therapies. The market will grow due to investments, collaboration, and AI's role in addressing rising chronic conditions.Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The \"AI in Drug Discovery Market, till 2040: Distribution by Drug Discovery Steps, Therapeutic Area, and Key Geographical Regions: Industry Tr",
      "url": "https://finnhub.io/api/news?id=b550283fed8c2379bd057fdd19efb3af9179be0faf1ae9f00d9360c8b9293071"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm",
    "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
    "url": "https://finnhub.io/api/news?id=9d842825b20436f44b0093a2ea31c53bcb7bbb2977ece838edeb27911a8ccd64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768797673,
      "headline": "1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm",
      "id": 138176350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
      "url": "https://finnhub.io/api/news?id=9d842825b20436f44b0093a2ea31c53bcb7bbb2977ece838edeb27911a8ccd64"
    }
  }
]